C4 Therapeutics to Present Initial CFT1946 Phase 1 Data at ESMO Congress 2024

C4 Therapeutics, Inc. (C4T), a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science, has announced new data from its ongoing Phase 1 clinical trial of CFT1946. This new compound is a BiDAC™ degrader aimed at treating patients with mutant BRAF V600 solid tumors. The information has been shared in an abstract released alongside the ESMO Congress 2024, which will take place from September 13 to 17 in Barcelona, Spain. The complete abstract, reflecting data up to April 12, 2024, is accessible on the ESMO Congress website.

The Phase 1 trial findings, based on data from 36 patients as of July 19, 2024, will be presented as a proffered paper at the ESMO Congress on Friday, September 13, 2024, at 4:10 pm CEST. The oral presentation will cover patient demographics, safety profiles, pharmacokinetic and pharmacodynamic data, as well as anti-tumor activity evaluated using RECIST 1.1 criteria.

The presentation, titled "Preliminary Results from a Phase 1 Study of CFT1946, a Novel BiDAC™ Degrader in Mutant BRAF V600 Solid Tumors," will be delivered by Dr. Maria Vieito. The session will take place in the Santander Auditorium at Hall 5 of the congress venue.

In addition to the ESMO Congress presentation, C4T has arranged a webcast for analysts and investors on September 13, 2024, at 12:00 pm ET. The webcast can be accessed via the company’s website, where a replay will be available after the event. The company will also share the ESMO presentation on its website under the Scientific Presentations and Publications section following the congress.

C4 Therapeutics is a biopharmaceutical company that focuses on developing targeted protein degradation therapies. Utilizing their TORPEDO® platform, C4T aims to design and optimize small-molecule medications to tackle difficult-to-treat diseases by leveraging the body's natural protein recycling mechanisms. These therapies could potentially address issues such as drug resistance and previously undruggable targets, thereby improving patient outcomes.

CFT1946, the subject of the Phase 1 study, is an orally bioavailable BiDAC™ degrader specifically designed to target BRAF V600X mutations. Preclinical studies have demonstrated its effectiveness both in vitro and in vivo, particularly in diseases driven by BRAF V600E mutations and in models that have developed resistance to existing BRAF inhibitors. Currently, CFT1946 is undergoing a Phase 1 dose escalation study involving patients with various BRAF V600X mutant solid tumors, such as colorectal cancer, melanoma, and non-small cell lung cancer. More details about this clinical trial can be found on the clinicaltrials.gov website under the identifier NCT05668585.

By developing innovative degrader medicines, C4 Therapeutics hopes to transform the treatment landscape for patients with challenging and resistant diseases, bringing new hope and improved outcomes to those affected.